Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the first ...
MedPage Today on MSN
Gene therapy-induced CAR T cells for myeloma could alter treatment landscape
MRD-negative status in first four heavily treated patients with "off the shelf" product ...
Dr Suchitra Sundaram shares key highlights on frontline time limited and all oral regimens producing deep MRD responses, ...
Kelonia Therapeutics' KLN-1010 has shown promising early results in a phase 1 trial for relapsed or refractory multiple ...
Natera's PALLAS study data show MRD status strongly predicts five-year recurrence risk in stage II–III HR+/HER2- breast ...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, together with Alliance Foundation ...
ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high ...
Sensitive tests designed to detect very small numbers of remaining leukemia cells after treatment, known as measurable ...
News-Medical.Net on MSN
Chemotherapy-based conditioning matches outcomes of total body irradiation for MRD-negative B-ALL
In a new trial, patients with B-acute lymphoblastic leukemia (B-ALL) who had no evidence of remaining cancer cells after ...
A tumor-informed ctDNA assay identified MRD in TNBC patients, indicating a 30-fold higher risk of distant recurrence for MRD-positive individuals. The NSABP B-59/GBG 96-GeparDouze trial involved 1550 ...
A conditioning regimen free from total body irradiation (TBI) appeared to be just as effective as standard of care (SoC) in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback